Throughout her 35-year career, Dr. Pamela Goodwin has become a global leader in breast cancer research.
Dr. Goodwin was the founding Director of Sinai Health’s Marvelle Koffler Breast Centre (MKBC). She led the MKBC for almost 25 years, before she stepped down in 2019 to focus on her research. Under her leadership, it was a model for breast centres across Canada and internationally. Her research team discovered important links between breast cancer outcomes and women’s lifestyles, environments, and individual bodies and is driving advances that are being employed in clinical practice to help patients, survivors and families.
Dr. Goodwin’s team reported that obesity increases a woman’s risk of dying from breast cancer. Their discovery that high insulin levels that commonly occur in obesity spur the growth and spread of cancer was novel and led to a generation of studies to develop interventions to reverse this risk.
In 2021, Dr. Goodwin announced the findings of a major international study on the use of the diabetes drug metformin to treat common types of breast cancer. The researchers found a potentially beneficial effect of metformin in individuals with a less common but aggressive form of the disease, called HER2-positive breast cancer.
Recruited to the Lunenfeld-Tanenbaum Research Institute in 1988, Dr. Goodwin regularly collaborates with scientists at the Princess Margaret Cancer Centre and the Princess Margaret Research Institute along with researchers across North America and Europe.
Dr. Goodwin has always been more than a scientist. Throughout her career she has remained deeply connected to breast cancer patients, translating her research findings into practical clinical programs to enhance women’s experiences and improve their outcomes.
Dr. Goodwin was the founding Director of Sinai Health’s Marvelle Koffler Breast Centre (MKBC). She led the MKBC for almost 25 years, before she stepped down in 2019 to focus on her research. Under her leadership, it was a model for breast centres across Canada and internationally. Her research team discovered important links between breast cancer outcomes and women’s lifestyles, environments, and individual bodies and is driving advances that are being employed in clinical practice to help patients, survivors and families.
Dr. Goodwin’s team reported that obesity increases a woman’s risk of dying from breast cancer. Their discovery that high insulin levels that commonly occur in obesity spur the growth and spread of cancer was novel and led to a generation of studies to develop interventions to reverse this risk.
In 2021, Dr. Goodwin announced the findings of a major international study on the use of the diabetes drug metformin to treat common types of breast cancer. The researchers found a potentially beneficial effect of metformin in individuals with a less common but aggressive form of the disease, called HER2-positive breast cancer.
Recruited to the Lunenfeld-Tanenbaum Research Institute in 1988, Dr. Goodwin regularly collaborates with scientists at the Princess Margaret Cancer Centre and the Princess Margaret Research Institute along with researchers across North America and Europe.
Dr. Goodwin has always been more than a scientist. Throughout her career she has remained deeply connected to breast cancer patients, translating her research findings into practical clinical programs to enhance women’s experiences and improve their outcomes.
Dr. Goodwin was the founding Director of Sinai Health’s Marvelle Koffler Breast Centre (MKBC). She led the MKBC for almost 25 years, before she stepped down in 2019 to focus on her research. Under her leadership, it was a model for breast centres across Canada and internationally. Her research team discovered important links between breast cancer outcomes and women’s lifestyles, environments, and individual bodies and is driving advances that are being employed in clinical practice to help patients, survivors and families.
Dr. Goodwin’s team reported that obesity increases a woman’s risk of dying from breast cancer. Their discovery that high insulin levels that commonly occur in obesity spur the growth and spread of cancer was novel and led to a generation of studies to develop interventions to reverse this risk.
In 2021, Dr. Goodwin announced the findings of a major international study on the use of the diabetes drug metformin to treat common types of breast cancer. The researchers found a potentially beneficial effect of metformin in individuals with a less common but aggressive form of the disease, called HER2-positive breast cancer.
Recruited to the Lunenfeld-Tanenbaum Research Institute in 1988, Dr. Goodwin regularly collaborates with scientists at the Princess Margaret Cancer Centre and the Princess Margaret Research Institute along with researchers across North America and Europe.
Dr. Goodwin has always been more than a scientist. Throughout her career she has remained deeply connected to breast cancer patients, translating her research findings into practical clinical programs to enhance women’s experiences and improve their outcomes.
Throughout her career, Dr. Goodwin has remained deeply connected to breast cancer patients, enhancing women’s experiences, and improving their outcomes.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
About Mount Sinai 100 Chairs
In 2023, Mount Sinai Hospital will mark its 100th anniversary. To honour the physicians and scientists who have made breakthrough discoveries and whose achievements have elevated Sinai Health’s reputation for world-class care, we are pleased to introduce our Mount Sinai 100 Chairs. These legacy chairs carry the names of Sinai Health’s most eminent trailblazers and will help recruit and fund the work of a new generation of clinicians and scientists, securing the next century of caring at Sinai Health. We invite you to help us imagine the next 100 years.
